

**RECEIVED  
CENTRAL FAX CENTER**

MAY 22 2006

TRIPEP.23AUSC2

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant : Sällberg, et al.  
Appl. No. : 10/719,619  
Filed : November 20, 2003  
For : VACCINES CONTAINING  
RIBAVIRIN AND METHODS OF  
USE THEREOF  
Examiner : Li, Bao Q.  
Group Art Unit : 1648

**CERTIFICATE OF FAX TRANSMISSION**

I hereby certify that this correspondence and all  
marked attachments are being transmitted via  
facsimile to the USPTO Central Fax No. (571)  
273-8300 on the date shown below:

May 22, 2006

(Date)

  
Eric S. Furman, Reg. No. 45,664**INTERVIEW SUMMARY**

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held  
between Examiner Li, Supervisor Campell and the undersigned on May 16, 2006.

Appl. No. : 10/719,619  
Filed : November 20, 2003

### SUMMARY OF INTERVIEW


The undersigned wishes to thank Examiner Li and Supervisor Campell for the courtesy extended to him during a personal interview on May 16, 2006. During the interview between the undersigned, Examiner Li and, Supervisor Campell, the restriction requirement, the claim objections, the enablement rejections under 35 U.S.C. § 112, first paragraph, the new matter rejections under 35 U.S.C. § 112, first paragraph, the provisional double patenting rejection, and the rejections under 35 U.S.C. § 103 raised in the Office Action mailed February 22, 2006 were discussed. The undersigned and the Examiner reached the following agreements: (1) Claims 34-43, 46-49, 51-52, 57-67 and 72-80 are linking claims and will be examined. (2) Claims 81-84 and 85-88 limit dependent Claims 51 and 66, respectively and the objection to the claims would be removed. (3) The enablement rejection would be removed in view of Applicants' disclosure. (4) The new matter rejection would be removed in view of Applicants' disclosure, and Applicants' proposed amendment to Claim 47 to recite "wherein said measuring comprises measuring levels of IgG" or "wherein said measuring comprises measuring levels of IgM." It was agreed that the proposed amendments were supported by the specification. (5). The double patenting rejection would be addressed by submitting a terminal disclaimer. (6) The § 103(a) rejection would be removed in view of Applicants' arguments.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: May 22, 2006

By:   
Eric S. Furman  
Registration No. 45,664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

2619787-052206

**Knobbe Martens Olson & Bear LLP**

Intellectual Property Law

550 West C Street  
Suite 1200  
San Diego CA 92101  
Tel 619-235-8550  
Fax 619-235-0176  
www.kmob.com

**RECEIVED**  
**CENTRAL FAX CENTER**

**USPTO FACSIMILE TRANSMITTAL SHEET**

Page 1 of 2

MAY 22 2006

Docket No.: TRIPEP.23AUSC2

**CUSTOMER NO. 20995**

Applicant : Sällberg, et al.  
App. No. : 10/719,619  
Filed : November 20, 2003  
For : VACCINES CONTAINING RIBAVIRIN  
AND METHODS OF USE THEREOF  
Examiner : Li, Bao Q.  
Group Art Unit : 1648

**CERTIFICATE OF FAX TRANSMISSION**

I hereby certify that this correspondence and all marked attachments are being transmitted via facsimile to the USPTO Central Fax No. (571) 273-8300 on the date shown below:

May 22, 2006

  
Eric S. Furgan, Ph.D., Reg. No. 45,664

Transmitted herewith for filing and consideration in the above-referenced application are the following items:

- (X) Amendment/Response in eighteen (18) pages.  
     (X) Non-Final  
     () After Final  
 (X) Terminal Disclaimer with attached assignment in five (5) pages.  
 (X) Interview Summary in two (2) pages.

**FILING FEES:**

FEE CALCULATION				
FEE TYPE		FEE CODE	CALCULATION	TOTAL
Total Claims minus 20; or Previously Paid	51 - 50 = 1	1202 (\$50)	1 x 50 =	\$50
Independent minus 3; or Previously Paid	4 - 4 = 0	1201 (\$200)	0 x 200 =	\$0
Terminal Disclaimer	37 CFR § 1.20(d)	1814 (\$130)		\$130
SUB TOTAL				\$180
The present application qualifies for Small Entity status under 37 CFR § 1.27. Fee reduced by 1/2.				(\$90)
TOTAL FEE DUE				\$90

(X) Please charge the total fees due in the amount of \$90 to Deposit Account No. 11-1410.

Orange County  
949-760-0404

San Francisco  
415-954-4114

Los Angeles  
310-551-3450

Riverside  
951-781-9231

San Luis Obispo  
805-547-5580

**Knobbe Martens Olson & Bear LLP**


Application No.: 10/719,619

Filing Date: November 20, 2003

**CUSTOMER NO. 20995**

(X) Total pages in transmission: 27

The Commissioner is hereby authorized to charge any additional fees which may be required, now or in the future, or credit any overpayment to Account No. 11-1410.

  
Eric S. Furman, Ph.D.  
Registration No. 45664  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

2620954 sma052206